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Abbreviations 81 
ADV   adenovirus 82 
BUMAC  myeloablative busulfan 83 
BURIC   reduced dose busulfan 84 
CID   combined immunodeficiency 85 
CMV   cytomegalovirus 86 
DOCK8   dedicator of cytokinesis 8 87 
EBV   Epstein-Barr virus 88 
GVHD   Graft versus Host disease 89 
HHV6   human herpesvirus 6 90 
HLA    human leukocyte antigen 91 
HSCT    hematopoietic stem cell transplantation 92 
HSV   herpes simplex virus 93 
MSD   matched sibling donor 94 
MFD   matched family donor 95 
MUD   matched unrelated donor 96 
MMFD   mismatched family donor 97 
PBSC   peripheral blood stem cells  98 
PFT   pulmonary function test 99 
RIC   reduced intensity regimen 100 
TBI   total body irradiation 101 
TREO    treosulfan based regimen 102 
UCB   umbilical cord blood 103 
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Abstract: 106 
Background: Biallelic variations in the DOCK8 gene cause a combined immunodeficiency with 107 
eczema, recurrent bacterial and viral infections, and malignancy. Natural disease outcome is dismal, 108 
but allogeneic hematopoietic stem cell transplantation (HSCT) can cure the disease. 109 
Objective: To determine outcome of HSCT for DOCK8 deficiency and define possible outcome 110 
variables. 111 
Methods: We performed a retrospective study of the results of HSCT in a large international cohort of 112 
DOCK8 deficient patients. 113 
Results: We identified 81 patients from 22 centers transplanted at a median age of 9.7 years (range: 114 
0.7-27.2) between 1995 and 2015. After median follow-up of 26 months (3-135), 68 of 81 patients are 115 
alive (84%). Severe acute (III-IV) or chronic graft versus host disease (GVHD) occurred in 11% and 116 
10% respectively. Causes of death wereinfections (n=5), GVHD (5), multi-organ failure (2) and pre-117 
existent lymphoma (1). Survival after matched related (n=40) or unrelated (35) HSCT was 89% and 118 
81%, respectively. Reduced toxicity conditioning based on either treosulfan or reduced-dose busulfan 119 
resulted in superior survival compared to fully myeloablative busulfan-based regimens (97% vs. 78%; 120 
p=0.049). 96% of patients aged <8 years at HSCT survived, compared to 78% of those ≥8 years 121 
(p=0.06). Of 73 patients with chimerism data available, 65 (89%) had >90% donor T-cell chimerism at 122 
last follow-up. Not all disease manifestations responded equally well to HSCT: eczema, infections and 123 
Mollusca resolved better than food allergies or failure to thrive. 124 
Conclusion: HSCT is curative in most DOCK8 deficient patients, confirming this approach as the 125 
treatment of choice. HSCT using a reduced toxicity regimen may offer the best chance for survival. 126 
 127 
Highlights box: 128 
1. What is already known about this topic? 129 
Biallelic variations in the DOCK8 gene cause a combined immunodeficiency with dismal natural 130 
disease outcome, which can be treated by allogeneic HSCT. 131 
2. What does this article add to our knowledge? 132 
HSCT with a reduced toxicity conditioning results in excellent survival and disease correction, 133 
regardless of donor type. 134 
3. How does this study impact current management guidelines? 135 
The encouraging results of this analysis may be helpful for patient counselling and guiding clinical 136 
decision making in future DOCK8 deficient patients. 137 
  138 
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Introduction 139 
 140 
Biallelic mutations or deletions in the gene encoding the dedicator of cytokinesis 8 (DOCK8) cause a 141 
combined T- and B- lymphocyte immunodeficiency (1, 2), characterized by severe and recurrent skin 142 
and systemic infections, severe allergic disease, and predisposition to malignancy (3, 4), and which 143 
had initially been described as the autosomal recessive variant of Hyper-IgE syndrome (5). After 144 
discovery of the causative gene in 2009, two larger cohorts have been published, both demonstrating 145 
the severity of this disease and its dismal outcome (3, 6, 7). Only about a third of patients reach age 30 146 
without HSCT and about 75% develop severe, life-threatening disease complications before age 20 147 
(6). 148 
Soon after, two case reports of patients, who had undergone HSCT long before genetic diagnosis was 149 
possible, demonstrated the possibility of cure with HSCT (8, 9). Several case reports and small case 150 
series on the outcome of HSCT with various donor types have since been published (10-17). Most of 151 
them report encouraging results, possibly skewed by publication bias. While these reports have been 152 
helpful in directing many patients with DOCK8 deficiency to earlier HSCT, it still remains unclear 153 
which conditioning regimens or donor types will yield the best outcomes. Furthermore, some of the 154 
case reports hinted at the fact that not all disease manifestations, notably food allergies, may be 155 
equally well corrected by HSCT (8, 11, 18). To address these questions, larger and more 156 
comprehensive HSCT cohorts need to be studied.  157 
Based on a multi-institutional retrospective chart-based review conducted on behalf of the inborn 158 
errors working party of the European Group for Blood and Marrow Transplantation (EBMT) and the 159 
European Society for Primary Immunodeficiencies (ESID) this manuscript reports on the largest 160 
cohort of DOCK8 deficient patients treated by HSCT so far.  161 
162 
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Methods 163 
 164 
Data accrual and statistics 165 
A case report form asking for pseudonymized chart-based data of transplanted patients was sent to 166 
authors of our previous paper on the DOCK8 phenotype (6) and to members of the inborn errors 167 
working party of the EBMT and ESID and was posted on the ESID website. The data collection 168 
concluded on 31.12.2016. This retrospective chart review received a waiver of approval by the ethics 169 
committee of the Ludwig-Maximilians-University of Munich, Germany. German patients or their 170 
respective caregivers gave their written informed consent for inclusion in the German pediatric stem 171 
cell transplantation registry (PRST) which was approved by the ethics committee of the Medizinische 172 
Hochschule Hannover. International centers had to receive approval for data transfer from their 173 
respective ethics committee or a waiver if applicable. Kaplan Meier survival estimates and cumulative 174 
incidence rates were compared using the log rank test (Prism 5, GraphPad, La Jolla, CA, USA). Other 175 
analyses utilized the chi-square or Fisher exact test and were accepted as significantly different at a 176 
level of p<0.05. 177 
Patients 178 
Included in this study were patients with a confirmed bi-allelic variation affecting the DOCK8 gene 179 
who underwent a first HSCT between 1.1.1995 and 31.12.2015. Partial information on 36 patients in 180 
this study was previously reported in the paper by Aydin et al (6).  181 
Definitions 182 
Unrelated donors were considered matched (MUD) if they were at least 9/10 or 10/10 HLA allele 183 
matched. Due to the different dosing regimens for i.v. and oral busulfan, all busulfan dosages were 184 
converted to a dose equivalent to oral dosing in order to make them comparable. Conditioning 185 
regimens containing busulfan were considered to be myeloablative if the total dose was equivalent to 186 
an oral dose of ≥14mg/kg or was targeted to an AUC of ≥70.000ngxml/h and reduced intensity when 187 
the total dose was <14mg/kg or targeted to an AUC of <70.000ngxml/h.  188 
GVHD was graded according to modified Glucksberg criteria for acute, and according to NIH 189 
consensus criteria for chronic GVHD (19, 20). Severe infections were defined as sepsis, meningitis, or 190 
pneumonia requiring hospitalization and supplemental oxygen or mechanical ventilation. 191 
The method for determining resolution of symptoms post HSCT was left at the local physician’s 192 
discretion.  193 
194 
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Results 195 
 196 
Patient and transplant details 197 
Data from 81 patients (43 female, 38 male) receiving a first HSCT from 22 centers in 11 countries 198 
were included. The median age at HSCT was 9.7 years (0.7 - 27.2). Donors were matched sibling 199 
donors (MSD) in 34 transplants, other matched family donors (MFD) in 6, mismatched family donors 200 
(MMFD) in 6, matched unrelated donors (MUD) in 33 and unrelated cord blood (UCB) in 2. Bone 201 
marrow was the preferred stem cell source, used in 63 patients, peripheral blood stem cells (PBSC) in 202 
16, and cord blood in 2. Conditioning was based on myeloablative busulfan (BUMAC) in 31 patients, 203 
while in 17 reduced doses of busulfan (BURIC) were used. A treosulfan-based regimen (TREO) was 204 
applied in 17 patients. In vitro T-cell depletion was applied in one MUD recipient and in four of the 205 
six MMFD recipients, while the two other MMFD had post-transplant cyclophosphamide. The median 206 
follow-up after HSCT was 26 months (3-135). More detailed patient and transplant information is 207 
given in table 1. 208 
 209 
Survival 210 
The entire cohort of 81 patients had a 2-year overall survival (OS) probability of 84 % (95% 211 
confidence interval 73%-91%; figure 1A) and potential outcome variables were tested. 212 
There was no significant survival advantage after HSCT from a MSD or MFD compared to a MUD 213 
with 2-year OS probabilities of 89% (73-96) and 86% (66-95), respectively. Recipients of a MMFD 214 
had a 2-year OS probability of 66% (20-90), which was also not statistically different to the other 215 
groups (p=0.18; figure 1B). The conditioning regimen did have an impact on HSCT outcome. Two-216 
year OS probabilities after TREO, BURIC, BUMAC, or any other reduced intensity regimen (RIC) 217 
were 100%, 94% (63-99), 78% (57-90) and 79% (47-93; p=0.25; figure 1C), respectively. Using either 218 
a TREO or BURIC regimen resulted in a significantly better OS at 97% (80-100) versus using 219 
BUMAC, which yielded an OS of 78% (57-90; p=0.049; figure 1D). The median age in this cohort 220 
was 9.7 years (range 0.7-27.2). It was therefore prudent to test the influence of age at HSCT on 221 
survival. However, no age cut-off resulted in a significant result. There was a trend towards better 222 
survival in patients receiving their HSCT below the age of 8 years versus above with 2-year OS of 223 
96% (74-99) and 78% (63-88; p=0.06), respectively (figure 1E). Lastly, the date of HSCT had a 224 
significant influence on survival. Patients transplanted from 2011 to 2015 had a 2-year OS of 92% 225 
(81-96) as compared to 57% (28-78) for those who had their HSCT from 1995 to 2010 (p=0.01; figure 226 
1F). Of the 13 deaths post HSCT, the most common cause of death was infection (n=5 patients; 227 
bacterial sepsis n=3, unknown=2), as well as infection associated with GVHD (n=5; bacterial sepsis 228 
n=2, fungal, n=1, viral n=2). Multi organ failure was reported as cause of death in 2 cases; 1 patient 229 
succumbed to a T-cell lymphoma, pre-existent before HSCT, which was not EBV-driven. Virus 230 
reactivation/infection in the immediate post-transplant period occurred in 31 patients and two of the 231 
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deaths were associated with viral disease (CMV and adenovirus). The frequency of virus 232 
infection/reactivation was statistically not different between surviving and deceased patients (p=0.547) 233 
(table 3). 234 
In summary, HSCT performed from a MSD/MFD or MUD after TREO or BURIC conditioning after 235 
2010 resulted in superior outcomes in this cohort. 236 
 237 
GVHD 238 
Acute GVHD was reported in 27 of 81 patients resulting in a cumulative incidence of 33%. Of these 239 
22 (27%) had a severity of grade II-IV and 9 (11%) of grade III-IV. Of the 73 patients alive at more 240 
than 100 days post HSCT 7 developed chronic GVHD (10%), 3 mild, 2 moderate and 2 severe by NIH 241 
consensus criteria. In 5 of the 13 deaths GVHD was a contributing factor. 242 
 243 
Engraftment and chimerism 244 
Of the 73 patients with chimerism data available at last follow up, 64/73 (88%) had a global donor 245 
chimerism of 90% or higher, 1/73 (1%) between 80% and 90%, 4/73 (5%) between 20% and 80% 246 
donor and 4/73 (5%) between 0% and 20% (figure 2A). Two of the 81 patients did not engraft, both 247 
died during or after second HSCT. One had received a T-cell depleted MMFD graft after BUMAC and 248 
one an UCB after non-myeloablative conditioning. The T-cell donor chimerism was 90% or higher in 249 
65/73 patients (89%), between 80% and 90% in 4/73 (5%), between 20% and 80% in 3/73 (4%) and 250 
between 0% and 20% in 1/73 (1%) at last follow up (figure 2B). Twenty-nine of the 31 patients (94%) 251 
receiving a BUMAC regimen had a global donor chimerism of 90% donor or higher, one had a 252 
chimerism of 40% and one rejected. Of the 28 patients with a TREO or BURIC regimen and with 253 
chimerism data available, donor chimerism was 90% or higher in 25 (89%) and between 20% and 254 
80% in 3 (11%). 255 
Thus, engraftment in this cohort was solid and there was no discernable effect of the intensity of the 256 
conditioning regimen on the degree of donor chimerism. 257 
 258 
Symptom resolution post HSCT 259 
In early single patient reports inconsistent resolution of DOCK8 deficiency related symptoms after 260 
successful HSCT was described. Thus, we asked for changes in disease related symptoms at last 261 
follow-up (median 26 months [3-135]). 262 
Eczema, mollusca and recurrent upper airway infections responded very well to HSCT. Eczema was 263 
reported as resolved or improved in 70/71 patients (99%) who suffered from it before HSCT and 264 
mollusca in 34/36 (94%) (figure 3A and B). Upper airway infections were described as less frequent 265 
than before HSCT or occurring at a normal frequency for age in 66/71 affected patients (93%) (figure 266 
3C). Food allergies and impaired pulmonary function tests (PFT) responded less to HSCT. Food 267 
allergies resolved or improved in 34/56 (61%) patients, and since 13/56 (23%) had not been exposed 268 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
to their specific allergens after HSCT, resolution or improvement was observed in 34 of those 43 269 
patients who had exposure to their respective allergens post HSCT (79%)  (figure 3D). Impaired PFT 270 
improved or normalized in 26/47 (55%) patients, stabilized in 12/47 (26%) and worsened in 2/47 (4%) 271 
(figure 3E). Of 47 patients who had failure-to-thrive, another frequent symptom of DOCK8 272 
deficiency, 30 (64%) normalized or were catching up, 8 (17%) were unchanged, 2 (4%) too old to 273 
catch up (no improvement post-puberty) and in 5 (11%) it was too early after HSCT to tell (figure 3F). 274 
Of 12 patients with malignancies before HSCT, 11 remained in remission at last follow-up. One 275 
patient with lymphoma progressed and died. Another patient who had total body irradiation (4Gy) as 276 
part of her conditioning developed secondary thyroid cancer 7 years after HSCT, was successfully 277 
treated and remains in remission 7 years later. Finally, the treating physicians were asked whether they 278 
thought their patients had benefitted from HSCT and 76/81 replied. The answer was “yes, definitely” 279 
for 65/76 patients (85%), “somewhat improved” for 2/76 (3%), “too early to tell for 3/76 (4%) and 280 
“patient died” for 6/76 (8%). 281 
In summary the vast majority of surviving patients had improvement or resolution of their disease 282 
related symptoms. 283 
  284 
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Discussion 285 
 286 
DOCK8 deficiency, which was initially described as autosomal recessive Hyper IgE syndrome, is a 287 
combined immunodeficiency (CID) with a high mortality rate (1, 2, 5). Single case reports of patients 288 
transplanted years before the causative gene had been identified showed that HSCT was curative (8, 289 
9). Two larger and partially overlapping cohorts later confirmed a poor natural disease outcome with 290 
patient survival of about 50% at age 20 in the absence of HSCT, as well as high rates of malignancy, 291 
life threatening infections or CNS events (6, 7). We present the data relating to HSCT outcomes in the 292 
largest cohort of DOCK8 deficient patients to date, and found that outcomes are generally good when 293 
HSCT was performed with a reduced toxicity regimen. All disease manifestations are potentially cured 294 
by HSCT. 295 
In general, patients with CID are thought to have a survival advantage if transplanted as children (21). 296 
This may be in part due to the development of PID related comorbidities that occur over time, and the 297 
desire to have an earlier intervention to prevent more significant disease complications. As the prior 298 
study by Aydin et al demonstrated, the majority of patients with DOCK8 deficiency will develop a 299 
life-threatening infection, CNS event or malignancy by age 20 (6). In this study with a median age at 300 
HSCT of almost 10 years we were not  able to identify an ideal age range for HSCT in DOCK8 301 
deficiency. A much larger study will be needed to make such a recommendation. It is still possible that 302 
HSCT has a favorable risk/benefit ratio in adolescents or young adults with DOCK8 deficiency. Out of 303 
16 patients with an age at HSCT of 16 years or higher in our cohort, 14 survived, which is in line with 304 
recent reports on good HSCT outcomes in adolescents and young adults with primary 305 
immunodeficiencies (22, 23). In a disease like DOCK8 deficiency which is characterized by severe 306 
systemic and cutaneous viral infections, it is expected that pre-existing viral disease in the host will 307 
result in more infectious complications during and after HSCT. In this cohort this was not the case. 308 
Only two of the 13 HSCT-associated deaths were in part attributed to viral disease and only 33% of 309 
patients experienced viral reactivation/infection. This means that while special attention should still be 310 
placed on prevention of virus infections after HSCT, the presence of pre-existing viral disease should 311 
not be an exclusion criterion for transplant. The reported incidence of severe acute and chronic GVHD 312 
in this cohort is low, given the high load of viral disease in DOCK8 deficiency. This may be caused by 313 
the fact that about half of the donors were MSD or MFD. This study showed no impact on OS with 314 
9/10 or 10/10 MUD compared to MSD/MFD. Our data may suggest that outcome after 315 
haploidentical HSCT in DOCK8 deficiency is inferior. However, two deaths in this very small group 316 
(n=6) occurred in the 1990-ies and all four patients transplanted with modern in-vitro or in-vivo T-cell 317 
depletion strategies (TCRαβ/CD19-depletion or post-transplant cyclophosphamide, n=2 each) 318 
survived. This encouraging outcome after MMFD HSCT in DOCK8 deficiency is in line with recent 319 
case reports (13, 16, 17). 320 
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This large multi-center patient series allows the analysis of the impact of different HSCT strategies on 321 
outcome. Although a wide variety of conditioning regimens were reported ranging from fully 322 
myeloablative to an unconditioned stem cell infusion in one patient (24), it was possible to compare 323 
fully myeloablative busulfan-based regimens to reduced toxicity regimens based on either busulfan or 324 
treosulfan, demonstrating a significant survival benefit for these reduced regimens. The fact that 89% 325 
of patients achieved >90% donor chimerism with these regimens indicates that regimens based on 326 
reduced doses of busulfan with or without pharmacokinetic monitoring or treosulfan - as they are 327 
currently recommended by the inborn errors working party of EBMT and ESID - may preferentially 328 
be used for patients with DOCK8 deficiency (25). It remains to be explored in the future whether 329 
patients with specific pre-HSCT comorbidities would require conditioning regimens with the degree of 330 
myeloablation and immunosuppression tailored to their specific needs. 331 
This study comprehensively analyses the correction of all disease related manifestations in DOCK8 332 
deficiency by HSCT. As expected from previous smaller case series, eczema and mollusca resolved or 333 
improved in almost all affected patients. The fact that food allergies only slowly regress after 334 
successful HSCT could be confirmed here, which may be explained by the long-lived nature of host-335 
derived, IgE-producing plasma cells (18). Impaired pulmonary function tests before HSCT did not 336 
improve or normalize in 30% of the patients within the relatively short follow-up period. This argues 337 
strongly for a strategy of transplanting patients before permanent lung damage has developed, as this 338 
may not only negatively impact their quality of life but also long-term survivorship. Most of the pre-339 
existing malignancies remained in remission after HSCT and only one patient developed thyroid 340 
cancer after HSCT, which may also have been caused by the irradiation containing conditioning. This 341 
suggests that the strong predisposition towards malignancy in DOCK8 deficiency is corrected or at 342 
least improved by HSCT, although long-term follow-up is still limited. This may be especially true for 343 
the malignancies of B-cell origin. Whether this also remains true for the cancers of epithelial origin, 344 
which are more frequent in DOCK8 deficiency than in other CID (6), remains to be evaluated in larger 345 
cohorts with a longer follow-up. The hope is that with good immune reconstitution and better control 346 
of HPV infection, the incidence of HPV related squamous cell carcinomas will decrease. In our 347 
previously published cohort of 136 DOCK8 deficient patients, 12.5% of patients were reported to have 348 
autoimmunity (6). In this current cohort none of the patients were reported to have had autoimmunity 349 
as a post HSCT complication or as a cause of death. Due to this relative infrequency, we did not 350 
investigate resolution of autoimmunity after HSCT.  351 
While this is the largest cohort of transplanted DOCK8 patients published to date, there are limitations 352 
to this study. Its retrospective and multicenter design may implicate a bias in selecting conditioning 353 
regimens for individual patients based on their clinical conditions. The relatively small numbers of 354 
patients, incomplete chimerism data and lack of immunological parameters post HSCT did not allow 355 
us to analyze the impact of lineage specific chimerism and immunological reconstitution on clinical 356 
outcome and symptom resolution. Ideally these should be studied in a prospective manner. An 357 
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increasing number of reports of vascular abnormalities including vasculitis have been reported in 358 
DOCK8 deficiency, which was not systematically assessed in this cohort. The outcome and long-term 359 
prognosis of patients with these complications should be addressed in future studies. It may also be 360 
possible that individuals with biallelic DOCK8 variations and an extremely mild clinical phenotype 361 
who don’t require HSCT may be discovered, even if no current publication suggests this. 362 
In summary this study confirms that patients with DOCK8 deficiency can expect excellent survival 363 
and disease correction if transplanted with modern HSCT strategies. We believe that the overall 364 
encouraging results of this analysis will be helpful for patient counselling and guiding clinical decision 365 
making in future DOCK8 deficient patients. 366 
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Tables 374 
Table 1: 375 
 376 
n= 81 
female/male 43/38 
median age at HSCT (years) 9.7 (0.7-27.2) 
donor type  
 MSD 34 
 MFD 6 
 MUD 32 
 MMUD 1 
HLA match 10/10  20 
  9/10  10 
  8/10  1 
  8/8  1 
  6/6  1 
 MMFD 6 
 UCB 2 
stem cell source  
 bone marrow 63 
 PBSC 16 
 cord blood 2 
conditioning  
 busulfan based 48 
  myeloablative  31 
   BU/CY   12 
   BU/FLU   19 
  reduced*  17 
 treosulfan based (all TREO/FLU) 17 
 other reduced intensity 14 
  with TBI (200-400cGy)  4 
 other myeloablative 1 
 none 1 
 serotherapy used 38 
 377 
Table 1: Patient and transplant characteristics. BU/CY: busulfan cyclophosphamide; BU/FLU: busulfan 378 
fludarabine; TREO/FLU: treosulfan fludarabine; MFD: matched family donor; MMFD: mismatched family 379 
donor; MSD: matched sibling donor; MUD: matched unrelated donor; MMUD: mismatched unrelated donor; 380 
PBSC: peripheral blood stem cells; TBI: total body irradiation; UCB: unrelated cord blood. 381 
*: busulfan i.v. dose equivalent to <14mg/kg p.o. or busulfan targeted to an AUC of <70.000ngxml/h 382 
 383 
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Table 2: 385 
acute GVHD 27/81 (33%) 
 I  5 (6%) 
 II 
 13 (16%) 
 III 
 6 (7%) 
 IV  3 (4%) 
 
 
 II-IV  22 (27%) 
 III-IV  9 (11%) 
  
chronic GVHD (f/u>100d) 7/73 (10%) 
 mild  3 (4%) 
 moderate  2 (3%) 
 severe  2 (3%) 
 386 
Table 2: GVHD. Incidences of acute and chronic GVHD.  387 
 388 
  389 
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Table 3: 390 
  time point 
 number of patients with virus 
infection/reactivation 
early (< day 100) late (> day 100) 
surviving 
(68/81) 
25/68 (37%) CMV 15 
EBV 4 
HSV 3 
ADV 4 
HHV6 1 
BK 2 
other 1 
EBV 2 
HSV 1 
VZV 2 
 
deceased 
(13/81) 
6/13 (42%) CMV 3 
EBV 2 
HSV 1 
HHV6 1 
CMV 1 (persistent) 
EBV 1 (persistent) 
ADV 1 
 391 
Table 3: Viral infections/reactivations in surviving and deceased patients. Frequency of virus 392 
infections/reactivations in surviving and deceased patients. A single patient may have had multiple viruses. The 393 
frequency of virus infection/reactivation was statistically not different between surviving and deceased patients 394 
(p=0.547). ADV: adenovirus; BK: human polyoma virus 1; CMV: cytomegalovirus; EBV: Epstein-Barr virus; 395 
f/u: follow-up; HHV6: human herpesvirus 6; HSV: herpes simplex virus; VZV: varicella zoster virus. 396 
 397 
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Figure legends 399 
 400 
Figure 1. Overall survival (OS). Kaplan-Meier analysis of overall survival post HSCT of the entire 401 
cohort (A), by donor type (B), by type of conditioning (C,D), by age at HSCT (E) and by the year of 402 
HSCT (F). BUMAC: busulfan-based myeloablative conditioning; BURIC: busulfan-based reduced 403 
intensity conditioning; RIC: reduced intensity conditioning; TREO: treosulfan-based conditioning. 404 
Figure 2: Chimerism at last follow-up. Donor chimerism at last follow-up in n=73 patients in whom 405 
data were available in whole blood (A) and in T-cells (B). 406 
Figure 3: Correction of disease related symptoms by HSCT. Treating physicians were asked how 407 
they rated the correction of symptoms associated with DOCK8 deficiency after HSCT. PFT: 408 
pulmonary function tests. 409 
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